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Abstract
Purpose: This study aimed to investigate the effects of injection 
site on the reflux after intravitreal injection.
Methods: One hundred and eighty eyes undergoing intravitreal in-
jection including 0.1 ml of triamcinolone acetonide or bevacizumab 
or pegaptanib were divided to six groups (30 patients in each group) 
to compare the vitreal reflux after injection using superotemporal 
versus inferotemporal quadrant. The amount of intraoperative re-
flux was estimated by measuring the width of the subconjunctival 
bleb. An interventional, prospective, comparative clinical trial was 
applied.
Results: The mean bleb width as the reflux amount after injection 
of three drugs was statistically less after the inferotemporal injec-
tion (1.50 ± 0.94 mm for triamcinolone acetonide, p < 0.001; 1.60 
± 1.07 mm for bevacizumab, p < 0.001; and 1.77 ± 0.94 mm for 
pegaptanib, p = 0.001) than those in eyes undergoing the supero-
temporal injection (3.20 ± 1.63 mm for triamcinolone acetonide; 
3.07 ± 1.53 mm for bevacizumab; and 2.80 ± 1.32 mm for pegap-
tanib).
Conclusion: The injection through inferotemporal quadrant pro-
vides statistically significant less vitreal reflux for intravitreal drug 
injection.
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Introduction
The use of intravitreal (IVT) drug injections for the treat-
ment of various refractory retinal diseases has increased rap-
idly in the current decade. Despite of the off-label use of 
IVT triamcinolone acetonide (TA) (Kenalog; Bristol-Myers 
Squibb, New York, NY) and bevacizumab injection, it has 
been reported that both drugs in intravitreal rate are efficient 
and safe agents in macular oedema and retinal neovascular-
ization [1-6]. Previous clinical and experimental trial data 
have demonstrated that the therapeutic aptamer oligonucle-
otide pegaptanib sodium (Macugen; Eyetech Pharmaceuti-
cals, New York, NY) and the monoclonal antibody fragment 
ranibizumab (Lucentis; Genentech, San Francisco, CA) are 
effective for the treatment of neovascular age related macu-
lar degeneration (AMD) [7-10]. 
Drug reflux is clinically important to drug efficacy or 
safety of IVT injections. The reflux has an important intra-
operative complication in IVT injections because the prob-
lems that could be associated with a vitreous or drug reflux 
are the misplacement of substantial amount of the injected 
drug, the vitreous wick and the increase in the risk of endo-
phthalmitis due to the entering of the bacteria from the ocu-
lar surface through injection site. It has been reported that the 
factors such as volume amount, injection speed, and length 
and direction of the scleral incision might have influence on 
amount of vitreal reflux after IVT injections. However, there 
was no report or consensus on the site or the quadrant loca-
tion that used for injection [11-21]. Thus, in this study we 
aimed to investigate the effects of injection site on the reflux 
following IVT injections.
 
Materials and Methods
Subjects and design
One hundred and eighty eyes of 180 patients with various 
retinal disorders who were taken under follow-up in the reti-
nal outpatient clinic of our university hospital were enrolled 
to this study. The study was designed as an interventional, 
prospective and comparative clinical trial. 
In  this  study,  the  indications  for  IVT  treatment  were 
proliferative diabetic retinopathy (n = 13), diabetic macular 
oedema (n = 53), macular oedema due to branch retinal vein 
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occlusion (n = 24) and central retinal vein occlusion (n = 12), 
and neovascular age-related macular degeneration (n = 78). 
All patients underwent a complete ophthalmologic and 
general examination. The tenets of the Helsinki declaration 
were followed throughout the study. Informed consent was 
obtained from each subject including detailed explanations 
of all procedures before participation in the study. 
The patients with disorders such as connective tissue 
disease, degenerative myopia and scleritis, which refers that 
scleral thickness may be affected, the patients with obesity 
and blepharospasm of whom the disorders may affect the re-
flux, and the patients who underwent intravitreal injection or 
vitrectomy prior to the study were excluded from study. 
Patients were divided to six groups: TA injection via the 
superotemporal quadrant (Group 1, n = 30), TA injection via 
the inferotemporal quadrant (Group 2, n = 30), bevacizum-
ab injection via the superotemporal quadrant (Group 3, n = 
30), bevacizumab injection via the inferotemporal quadrant 
(Group 4, n = 30), pegaptanib injection via the superotempo-
ral quadrant (Group 5, n = 30), and pegaptanib injection via 
the inferotemporal quadrant (Group 6, n = 30).
The pars plana injection technique
Before the injection is administered, Oxybuprocaine hydro-
chloride drop and 10% povidone-iodine wash using a flush 
injector were applied directly to the ocular surface, lid mar-
gins, and lashes. After a lid speculum was placed, an addi-
tional drop of povidone-iodine and topical anaesthetic was 
applied to the intended injection site. No instrumentation 
was performed for the globe fixation during the injection be-
cause the potential elevation of intraocular pressure due to 
fixation might influence reflux.
Injection was performed by the surgeon (B.T.) through 
the pars plana using a 27-gauge needle on a 1-ml tuberculin 
syringe in temporal quadrants 3 mm (pseudophakic eyes) to 
4 mm (phakic eyes) from the limbus, and then 0.1 ml with 
4 mg TA or 2.5 mg bevacizumab or 0.3 mg pegaptanib was 
injected into the mid vitreous cavity. The standard straight 
injection perpendicular to the sclera was slowly created af-
ter upward mobilization of the conjunctiva and the syringe 
needle was then gently withdrawn. In order to avoid vitreous 
wick syndrome, the conjunctiva shifted with a cotton-tipped 
applicator before injection and then, to minimize reflux, this 
applicator was softly applied over the scleral entry site to the 
needle withdrawn for about three seconds. 
In all the six groups, the amount of vitreal reflux was 
assessed by measuring the width of the broadest conjunc-
tival elevation of the subconjunctival bleb with a surgical 
calliper described by Rodriques [22]. Intraocular pressures 
(IOP) were measured 30 minutes later after the injection in 
all patients.
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences version 13.0 (SPSS, Inc., Chi-
cago, IL, USA). The Student t test was used to estimate dif-
ferences within and among the study groups. Results were 
given as means + standard deviations. P value less than 0.05 
was considered as statistically significant.
 
Results
One hundred and thirty two patients were phakic, and 48 
were  pseudophakic.  Sixty-one  percent  of  patients  were 
women and 39% were men. Mean age was 68.6 ± 7.2 years 
(range, 54 to 77 years) in Group 1, 65.4 ± 5.9 years (range, 
56 to 76 years) in Group 2, 67.2 ± 8.3 years (range, 58 to 83 
years) in Groups 3, 64.8 ± 9.2 years (range, 52 to 83 years) 
in Group 4 (range, 60 to 80 years), 66.6 ± 8.1 years (range, 
51 to 74 years) in Group 5, and 69.6 ± 6.2 (range, 62 to 76 
years) in Group 6.
The mean scales ± standard deviations (SD) of reflux 
width obtained with measuring the broadest conjunctival el-
evation after IVT injection were 3.20 ± 1.63 mm in Group 1, 
1.50 ± 0.94 mm in Group 2, 3.07 ± 1.53 mm in Group 3, 1.60 
± 1.07mm in Group 4, 2.80 ± 1.32 mm in Group 5, and 1.77 
± 0.94 mm in Group 6 (Table 1). 
The mean vitreal reflux width of the broadest conjuncti-
val elevation after TA injection was statistically greater with 
injection in superotemporal quadrant in Group 1 (3.20 ± 1.63 
mm) compared with the injection in inferotemporal quadrant 
in Group 2 (1.50 ± 0.94. mm) (p < 0.01).
The mean vitreal reflux width of the broadest conjunc-
tival elevation after bevacizumab injection was statistically 
greater with injection in superotemporal quadrant in Group 
3 (3.07 ± 1.53 mm) compared with the injection in infero-
temporal quadrant in Group 4 (1.60 ± 1.07 mm) ( p < 0.001).
The mean vitreal reflux width of the broadest conjunc-
tival elevation after bevacizumab injection was statistically 
greater with injection in superotemporal quadrant in Group 
5 ( 2.80 ± 1.32 mm) compared with the injection in infero-
temporal quadrant in Group 6 ( 1.77 ± 0.94 mm) ( p = 0.001).
When all groups were compared, it has been found that 
the mean vitreal reflux width with injection in superotem-
poral quadrants (Group 1, 3 and 5) was significantly higher 
compared to those in inferotemporal quadrants (Group 2, 4 
and 6) (p < 0.001) (Fig. 1). Neither the differences in reflux 
among Groups 1, 3 and 5 nor among Groups 2, 4 and 6 were 
found to be statistically significant (p > 0.05). 
Along the follow-up period lasting the mean 24 weeks, 
no complication due to IVT injection was detected in the pa-
tients. The IOP difference among all the groups was not sig-
nificant (p > 0.05). The mean IOP measurements and Stan-
dard deviations were given in Table 1. 
Subconjunctival  hemorrhage  following  injection  was 
occurred in 3 patients in group 1, in 2 patients in group 2, in 
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one patient in group 3, in 2 patients in group 4, in 2 patients 
in group 5, and in 3 patients in group 6. However, this did not 
influence the amount of reflux and the assessment of width 
of bleb because these patients had no reflux. 
There was either no significant difference among the 
mean age and the numbers of phakic and pseudophakic pa-
tients in the groups.
Discussion
  
The use of intravitreal injections has been now commonly 
chosen by retina specialists in the treatment of retinal disease, 
and it provides numerous advantages over other methods of 
administering drugs to the posterior segment such as effi-
cient intraocular concentrations and low systemic exposure. 
Despite  that  the  descriptions  of  IVT  injection  techniques 
were insufficient, the variables were described in the injec-
tion procedure such as the prophylactic and postoperative 
antibiotic therapy, the anaesthesia and antisepsis of the injec-
tion site, the controlling postoperative elevations in IOP, the 
injection quadrant, distance from limbus, and the provision 
of eye immobilization [12-16]. It has been also reported that 
the factors such as volume amount, injection speed, length 
and direction of the scleral incision, the needle size, the con-
sequential rise in IOP, and the injection technique used might 
have influence on amount of vitreal reflux after IVT injec-
tions. However, there was no report or consensus on the site 
or the quadrant location that used for injection except the 
direction of the needle towards the centre of vitreous cavity 
[11-21].
During removal of the needle following IVT injection, 
vitreous, liquefied vitreous or fluid can reflow through the 
needle incision into the subconjunctival space. The reflux 
after intravitreal injection can be observed in about 20% of 
injections [17]. The problems that could be associated with 
a vitreous or drug reflux are the misplacement of substantial 
amount of the injected drug, the vitreous wick syndrome and 
the increase in the risk of endophthalmitis due to the enter-
ing of the bacteria from the ocular surface through injection 
site [18, 19]. 
Although a straight needle path, pointing at the centre 
of the eyeball is usually recommended, in order to lower the 
risk of vitreous reflux, it has been recommended of using 
sharp smallgauge needles (27 gauge needle for Triamcino-
lone and 30 gauge needle for other drugs) or using a slightly 
angled scleral path with the injection needle, a short scleral 
tunnel for injection and pulling the conjunctiva over the in-
Figure 1. Box plot Graphics demonstrates the amount of reflux 
after the injection.
Groups Subconjunctival Bleb 
Diameters(Mean ± SD)
IOP Measurements
(Mean ± SD)
Group 1 (IVTA-Superotemporal Injection) 3.20 ± 1.63 mm 17.6 ± 4.1 mm Hg
Group 2 (IVTA-Inferotemporal Injection) 1.50 ± 0.94 mm  19.0 ± 4.7 mm Hg
Group 3 (IVB-Superotemporal Injection) 3.07 ± 1.53 mm 15.3 ± 3.1 mm Hg
Group 4 (IVB-Inferotemporal Injection) 1.60 ± 1.07 mm  16.8 ± 3.5 mm Hg
Group 5 (IVP-Superotemporal Injection) 2.80 ± 1.32 mm 18.4 ± 4.4 mm Hg
Group 6 (IVP-Inferotemporal Injection) 1.77 ± 0.94 mm  20.1 ± 5.2 mm Hg
P value P < 0.05  Group 1 vs. Group 2
P < 0.05 Group 3 vs. Group 4
P < 0.05 Group 5 vs. Group 6
P > 0.05  for all the groups
Table 1. The Reflux Amounts and the IOP Measurements After the İnjection (Mean ± SD) in the Study 
Groups
IVTA: Intravitreal Triamcinolone; IVB: Intravitreal bevacizumab; IVP: Intravitreal pegaptanib.
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jection site [18-21]. Recently, Rodriques et al [22] reported 
that the tunnelled scleral incision provides less vitreal reflux 
following IVT drug injection. Additionally, Lopez-Guajardo 
et al [23] demonstrated that the use of the oblique injection 
technique could reduce drug loss after intravitreal pegap-
tanib injection. In case that we focused on the effect of in-
jection quadrant on the reflux, the straight scleral injection 
was created in all the patients.
It was also considered that the vitreous changes due to 
aging may influence the reflux. However, there was no sig-
nificant difference among the mean age in the study groups.
Concerning with the location of the needle penetration 
into the vitreous, most studies reported that penetration was 
created in 3 mm in aphakic or pseudophakic eyes and in 4 
mm in phakic eyes posterior to the corneoscleral limbus. Lo-
cation of the injected material may strongly affect distribu-
tion of the compound within the vitreous, bioavailability and 
retinal toxicity [1, 2, 7, 16-18]. In our study, all the incisions 
were made between 3.0 and 4.0 mm posterior to the limbus, 
depending on the lens status. 
In  IVT  injections,  the  volume  of  administered  com-
pound was generally suggested 0.1 ml [24]. In this study, 
the standardized volume of administered compound for all 
injections was 0.1 ml.
The use of 27 or 30-gauge needles measuring between 
12.7 and 15.75 mm long and the advancement of the needle 
6 - 7 mm toward the centre of the eyeball to avoid injec-
tion along the anterior vitreous surface are usually recom-
mended [18]. In order to standardize, 27-gauge needles with 
12.7 mm length were used in incision and the needles were 
advanced 6 mm towards mid vitreous cavity.
In our study it was found that vitreal reflux was lesser in 
injection using inferotemporal quadrant compared to those 
in superotemporal quadrant. To the best knowledge, there 
is no data involving the thickness difference among differ-
ent scleral quadrants. Only, it has been known that the hu-
man sclera gradually thickens from the equatorial regions 
towards the posterior to reach a maximum thickness [25].
On the other hand, a variety of diseases or conditions in-
cluding vasculitis, ocular surface diseases, ocular infections, 
scleritis, episcleritis, collagen or connective tissue disorders, 
glaucoma, degenerative myopia, prior trabeculectomy with 
MMC or vitrectomy, may cause the thinning of scleral wall 
or the decreasing in scleral rigidity [26-29]. Thus, the pa-
tients with disorders mentioned above which may affect the 
scleral thickness and rigidity were excluded from study. 
The results from our study may be due to that thickness 
of the sclera in inferotemporal region is more than those in 
superotemporal. If this is demonstrated, less reflux in this 
quadrant may be explained. However, the measuring of the 
scleral thickness in different quadrants using preferably ul-
trasound biomicroscopy may explain our results.
In conclusion, we consider the usage of the inferotem-
poral quadrant for the performing intravitreal injections be-
cause the use of this site can result in reduced drug loss after 
intravitreal injections. When the amount of the drug within 
reflux should be detected, the effect of reflux on the efficacy 
of the drug administered through intravitreal rate could be 
understood. Future studies in humans and animals are need-
ed to determine the relationship between the vitreal reflux 
bleb and amount of drug volume loss after IVT injection. 
The next step is to investigate the reflux degree in pseu-
dophakic and phakic eyes, the possible effect of the usage 
of 30-gauge needle for injection, of the laterality of the eye 
injected and gender differences on the degree of reflux in 
more comprehensive studies.
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